Medical guidelines acknowledge apoB as superior risk marker, yet LDL remains standard
Despite evidence suggesting apoB could prevent more heart attacks and strokes, clinical inertia and the established success of statins have slowed its adoption in routine care.
In March 2026, the American Heart Association and the American College of Cardiology updated their cholesterol guidelines to acknowledge apolipoprotein B (apoB) as a potentially more precise marker for cardiovascular risk than low-density lipoprotein (LDL) cholesterol. This shift aligns with earlier European recommendations and recognises that apoB measures the total number of cholesterol-carrying particles in the blood, offering a clearer risk profile than LDL, which only measures the cholesterol content within those particles.
However, the updated guidelines stopped short of recommending apoB as the primary testing method. Instead, LDL remains the standard of care for clinical decision-making. Cardiologist Allan Sniderman, who authored a 2026 JAMA modelling study analysing data from around 250,000 US adults, noted that while the evidence ranks apoB as superior, the actual rules of the road continue to prioritise LDL.
The 2026 JAMA modelling study found that using apoB to guide treatment decisions would prevent more heart attacks and strokes than current LDL-focused approaches while remaining cost-effective. Recent research further indicates that in patients already taking statins, high levels of apoB and non-HDL cholesterol remain associated with increased risk of heart attacks and mortality, whereas LDL cholesterol levels do not show the same predictive power in this specific group.
Despite these findings, clinical inertia and the established success of LDL-targeting treatments like statins have slowed the adoption of apoB in routine care. For decades, LDL cholesterol has been both a scientific breakthrough and a public health success story, creating a powerful narrative that lowering it saves lives. This simplicity has limited how risk is understood, leaving many patients and physicians with little knowledge of apoB.
Experts suggest that if lipid testing were designed from scratch today, it would involve three parallel tests: LDL cholesterol, remnant cholesterol, and lipoprotein(a), rather than relying on a single measure. While apoB captures the total number of particles, clinicians must still understand what is driving the elevation, as it could stem from high LDL, insulin resistance, obesity, or genetic factors.
Beyond apoB, researchers are beginning to explore even more granular ways of measuring risk by combining metabolic data with genetic information. These large-scale analyses highlight the complex interplay of biological pathways in cardiovascular health, suggesting that medicine must move away from single-number diagnostics toward more layered, data-driven assessments of risk.
